Market News AIOpen the app

VVOS stock news · Vivos Therapeutics, Inc.

Stories about Vivos Therapeutics, Inc. (VVOS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for VVOS

Follow Vivos Therapeutics, Inc. (VVOS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VVOS
Free on the App Store and Google Play, or on the web.
  1. Oct 21, 2026, 7:20 AM ET · Market

    Vivos Therapeutics, Inc. says Nasdaq confirmed it meets the minimum requirements for stockholder equity.

    Neutral

    Vivos Therapeutics was told it meets Nasdaq’s stockholders’ equity rule, but it must show this again in its next report or could face delisting. The filing leaves its listing status unsettled.

  2. Oct 19, 2026, 5:15 PM ET · Market

    12 health care stocks changed a lot during Monday's after-hours trading.

    Neutral

    Vivos shares rose 18% in after-hours trading, but the article gives no business update or reason. The move alone does not change the outlook for Vivos.

  3. Oct 19, 2026, 4:57 PM ET · Deal

    Vivos Therapeutics, Inc. has signed an important deal with SOD Sciences to buy a small ownership stake.

    Neutral

    VVOS gained an 11% stake in SOD and half of its test rights, but issued convertible preferred shares. Without sales or profit estimates, the deal does not change its outlook.

  4. Aug 14, 2026, 6:43 PM ET · Results

    Q2 2026 results delivered by Vivos Therapeutics: Complete earnings call transcript available.

    Good for VVOS

    Vivos Therapeutics' Q2 2026 earnings report revealed a substantial revenue increase and strategic growth initiatives, including an acquisition, which positions the company favorably for future profitability. This news is likely to attract investor interest and support a bullish sentiment in the market.